Alyeska Investment Group L.P. purchased a new stake in shares of Portola Pharmaceuticals Inc (NASDAQ:PTLA) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 11,600 shares of the biopharmaceutical company’s stock, valued at approximately $627,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Hanseatic Management Services Inc. lifted its position in shares of Portola Pharmaceuticals by 0.3% in the 2nd quarter. Hanseatic Management Services Inc. now owns 22,800 shares of the biopharmaceutical company’s stock worth $1,281,000 after purchasing an additional 70 shares during the period. IFP Advisors Inc lifted its position in shares of Portola Pharmaceuticals by 7.7% in the 2nd quarter. IFP Advisors Inc now owns 2,370 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 170 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Portola Pharmaceuticals by 14.2% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,078 shares of the biopharmaceutical company’s stock worth $117,000 after purchasing an additional 258 shares during the period. Amalgamated Bank lifted its position in shares of Portola Pharmaceuticals by 5.4% in the 2nd quarter. Amalgamated Bank now owns 6,376 shares of the biopharmaceutical company’s stock worth $358,000 after purchasing an additional 328 shares during the period. Finally, Principal Financial Group Inc. lifted its position in shares of Portola Pharmaceuticals by 0.6% in the 2nd quarter. Principal Financial Group Inc. now owns 62,693 shares of the biopharmaceutical company’s stock worth $3,521,000 after purchasing an additional 371 shares during the period. 87.45% of the stock is owned by institutional investors and hedge funds.

Portola Pharmaceuticals Inc (NASDAQ:PTLA) opened at $47.55 on Friday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 8.31 and a current ratio of 8.31. Portola Pharmaceuticals Inc has a 12 month low of $17.74 and a 12 month high of $67.10.

Portola Pharmaceuticals (NASDAQ:PTLA) last issued its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($1.41) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.49) by $0.08. The company had revenue of $3.83 million during the quarter, compared to analyst estimates of $4.71 million. Portola Pharmaceuticals had a negative net margin of 938.19% and a negative return on equity of 110.46%. Portola Pharmaceuticals’s quarterly revenue was down 58.9% compared to the same quarter last year. During the same period last year, the business earned ($1.64) EPS. sell-side analysts expect that Portola Pharmaceuticals Inc will post -4.95 EPS for the current fiscal year.

Several equities research analysts have recently commented on the stock. Oppenheimer reaffirmed a “buy” rating and issued a $80.00 target price on shares of Portola Pharmaceuticals in a research report on Wednesday, September 6th. BidaskClub raised shares of Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 25th. Credit Suisse Group raised shares of Portola Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $70.00 target price for the company in a research report on Wednesday, August 23rd. Morgan Stanley reaffirmed an “overweight” rating and issued a $81.00 target price (up from $75.00) on shares of Portola Pharmaceuticals in a research report on Friday, October 6th. Finally, Goldman Sachs Group assumed coverage on shares of Portola Pharmaceuticals in a research report on Friday, December 1st. They issued a “buy” rating and a $75.00 target price for the company. One analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Portola Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $71.15.

ILLEGAL ACTIVITY WARNING: This report was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.dailypolitical.com/2017/12/15/11600-shares-in-portola-pharmaceuticals-inc-ptla-acquired-by-alyeska-investment-group-l-p.html.

About Portola Pharmaceuticals

Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

Institutional Ownership by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.